Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
About this item
Full title
Author / Creator
Publisher
MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
MDPI AG
Subjects
More information
Scope and Contents
Contents
Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central nervous system. Initially, it was considered that...
Alternative Titles
Full title
Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8084b1770446437c8f2227c31f486c13
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8084b1770446437c8f2227c31f486c13
Other Identifiers
ISSN
2076-3425
E-ISSN
2076-3425
DOI
10.3390/brainsci10110802
